Welcome to YLOAN.COM
yloan.com » Medical » Aarkstore Enterprise -china Pharmaceutical Guidebook: Latest Chinese Regulations For Imported Drug R
Health Medical Acne Aerobics-Cardio Alternative Anti-Aging Build-Muscle Chronic-Illness Dental-Care Depression Diabetes Disability Exercise Eye-Care Fitness-Equipment Hair-Loss Medicine Meditation Nutrition Obesity Polution Quit-Smoking Sidha Supplements Yeast Infection H1N1 Swine Flu SARS herpes therapy panic surgeon hurts teeth remedies eliminate chiropractic arthritis ingredients syndrome binding anxiety surgery medication psychic dental reflux doctor relief premature emotional stress disorder implants wrinkles vision infection aging liposuction seattle stunning sweating hair treatment tinnitus

Aarkstore Enterprise -china Pharmaceutical Guidebook: Latest Chinese Regulations For Imported Drug R

China Pharmaceutical Guidebook: Latest Chinese Regulations for Imported Drug Registration


China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2006, sales on the Chinese drug market have reached $12 billion dollars, an increase of 3.8 fold over 1998 level. A series of factors, such as an increasingly ageing population, accelerating growth of urban population as well as expansion of healthcare covering urban and rural, will grow the Chinese drug market with a growth rate of 20-25 percent per annum in next five years. China is expected to become the fifth largest drug market in the world by 2010.

Since the reform and open door policy implemented by Chinese authorities in the late 1970s, the door of the Chinese drug market began opening up to the world step by step, which gave a fillip to the imported drugs from overseas pharmaceutical manufacturers and producers. By 2006, sales of imported drugs have shared one fifth on the Chinese drug market. As China joins the World Trade Organization (WTO) and integrates more completely into the global economy, it will further open the door to a lucrative drug market for overseas pharmaceutical companies. More and more overseas pharmaceutical manufacturers and producers expect to enter such drug market and seize a larger part of such drug market. To enter such a lucrative drug market, the first obstacle faced by overseas pharmaceutical manufacturers and producers is how to file the application for their imported drug registration with Chinese pharmaceutical authorities. In China, the process of application and approval for imported drug registration is very complex, because the Chinese pharmaceutical authorities administer and control this process by exorbitant administrative measures and regulations, moreover, these exorbitant administrative regulations are variable and lack of transparency. Therefore, a comprehensive and thorough knowledge of the latest Chinese regulations for imported drug registration has been become an essential prerequisite for overseas pharmaceutical manufacturers and producers to achieve a successful application for their products entry into the Chinese drug market. In despite of since the drug registration implemented by the Chinese pharmaceutical authorities on December 1, 2002, its regulatory regime has experienced countless changes, and become increasingly compatible with international standards, in turn, its ongoing consolidation will eventually contribute to a healthier market environment. In July 2007, the Chinese pharmaceutical authorities promulgated the latest Measures for the Administration of Drug Registration, and the latest Measures will enter into force since October 1, 2007. These Measures provide the latest detailed requirements and procedures of application and approval for imported drug registration. Under such circumstance. The aim of this guidebook is to guide overseas pharmaceutical manufacturers and producers to achieve a successful application and approval for their imported drug registration. This guidebook is composed of four main parts as the following.

A Comprehensive Guidance of Imported Drug Registration


A Guidance of Registration Application for Imported Chemical Drugs

A Guidance of Registration Application for Imported Biological Products

A Guidance of Registration Application for Imported Natural Medicines and Traditional Chinese Medicines

Part I provides a comprehensive guidance of imported drug registration, which introduces an overview of the main responsibilities and organization structure of the Chinese pharmaceutical authority ---- State Food and Drug Administration (SFDA), the comprehensive regulations for imported drug registration in China, from the classification of drugs, definitions relating to application for imported drug registration, the application and approval for imported drugs and repackaging of imported drugs, the supplementary application and re-registration for imported drugs, the clinical investigation for application of imported drug registration to the time limits in drug registration, as well as the procedures of application and approval for imported drug registration, including the procedures of the initial application and approval for imported drugs, the supplementary application and approval for imported drugs, and the application and approval for clinical trials relating to imported drugs. All such knowledge in Part I is essential to achieve a successful application and approval for imported drug registration in China.

In China, like in other Western countries, the pharmaceutical authority ---- SFDA requests applicant to submit complicate and reliable materials for application of imported drug registration. Therefore, to achieve a successful application and approval for imported drug registration in China, overseas pharmaceutical manufacturers and producers must understand the more depth and detailed regulations on registration application for various imported drugs.

Part II provides a guidance of registration application for imported chemical drugs, which addresses SFDAs requirements for materials and clinical trials of application and approval for imported chemical drug registration, including radioactive pharmaceuticals, from the classification of drug registration formulated by the SFDA, the material items for application of chemical drug registration, the requirements of material items for application of chemical drug registration, the requirements of clinical trial for application of chemical drug registration to the material and clinical trial requirements for application of radioactive pharmaceuticals.

Part III provides a guidance of registration application for imported biological products. The biopharmaceutical industry is one of the burgeoning industries. In the field of biopharmaceuticals, vast knowledge awaits people to explore. The biopharmaceuticals are diversified and complex. In China, the development of biopharmaceutical industry is far behind the developed countries. Just for this reason, the requirements of materials and clinical trials for registration application of biopharmaceuticals stipulated by the Chinese pharmaceutical authority are far from systematic and uniform. In China, the SFDA divided the biopharmaceuticals for registration application into two classifications, i.e. the therapeutic biological products and the prophylactic biological products. However, in the classification of therapeutic biological products, the SFDA does not provide the uniform requirements of materials and clinical trials for registration application of biological products for the gene therapy, the somatic cell therapy and the allergic therapy, but stipulates the other guidelines for them. Therefore, the requirements for materials and clinical trials of registration application for imported gene therapeutic biological products, imported somatic cell therapeutic biological products and imported allergic therapeutic biological products are addressed based on these guidelines. Part III addresses the requirements of material items and clinical trials for registration application of imported therapeutic biological products and prophylactic biological products, as well as the imported biological products for the gene therapy, the somatic cell therapy and the allergic therapy, from the classification of therapeutic biological product and prophylactic biological product registration formulated by the SFDA, the material items for registration application of therapeutic biological products and prophylactic b

For more information, please contact :

http://www.aarkstore.com/reports/China-Pharmaceutical-Guidebook-Latest-Chinese-Regulations-for-Imported-Drug-Registration-1164.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise


Contact:Minu

Email: press@aarkstore.com

URL: www.aarkstore.com

by: aarkstore enterprise
Hoodia Gordonii Diet plan Drugs - A Fat Loss Assessment Diabetic Nephropathy and Intervention in Unani System of Medicine Make Your Knee Pain Disappear With Out Taking Drugs Or Injections Outsource Medical Transcription to Save Time and Money Closure to Anna Nicole Smith Drug Trial Case Alternative Gout Medicine Finding Articles On Drug Addiction And Recovery Medical Condition Piles - If You Suffer From This Condition, Read the Secrets For Piles Cures Here Urgent Medical Care Is Considered Necessary? The things to Examine for in a Alberta Recovery and Drug Treatment Center Cave dwelling medical researchers ascertained the consequences of CCSVI. Why cant we? Medical Billing and Coding Service - Benefits for Medical Practices New Tips - The Newest Drug For Impotence!
print
www.yloan.com guest:  register | login | search IP(216.73.216.20) California / Anaheim Processed in 0.019880 second(s), 7 queries , Gzip enabled , discuz 5.5 through PHP 8.3.9 , debug code: 36 , 8117, 92,
Aarkstore Enterprise -china Pharmaceutical Guidebook: Latest Chinese Regulations For Imported Drug R Anaheim